Vitamin D5 is a member of the vitamin D family that most people have never heard of, a compound called sitocalciferol derived from a plant sterol rather than the animal- or fungal-origin precursors behind the familiar D3 and D2. It does not appear in dietary supplements for a convergence of reasons: limited evidence of nutritional benefit, poor intestinal absorption compared to its cousins, and a research history focused almost entirely on experimental cancer prevention rather than bone health or general wellness. The story of D5 is less about a vitamin that got overlooked and more about a molecule that found a different, narrower lane in biomedical science.
What Vitamin D5 Actually Is
The vitamin D “family” is not just D2 and D3. Researchers have identified forms numbered D2 through D7, each derived from a different sterol precursor. Vitamin D5, or sitocalciferol, comes from 7-dehydrositosterol, which is related to beta-sitosterol, a plant sterol found widely in nuts, seeds, and vegetable oils. The conversion process mirrors how your skin makes D3 from 7-dehydrocholesterol when exposed to ultraviolet light: UV radiation breaks a specific chemical bond in the sterol ring, and a subsequent heat-driven rearrangement produces the vitamin D form. In the laboratory, researchers have synthesized D5 alongside D4, D6, and D7 by irradiating commercially available beta-sitosterol with UV light at 280 nm and then heating the product.1PubMed Central. Simultaneous Synthesis of Vitamins D2, D4, D5, D6, and D7 from Commercially Available Phytosterol, β-Sitosterol, and Identification of Each Vitamin D by HSQC NMR
So vitamin D5 is not some exotic invention. It is a naturally occurring member of a family of secosteroids, all sharing the same basic backbone but differing in the side chain attached to the molecule. That side chain difference, however, turns out to matter a great deal for how the body absorbs and uses each form.
How D5 Differs from D2 and D3
Vitamins D2 (ergocalciferol, from fungi) and D3 (cholecalciferol, from animal sources and sunlight) are the two forms used in virtually all supplements and fortified foods worldwide. Both are efficiently absorbed by intestinal cells and converted through well-characterized liver and kidney steps into active hormonal forms. D3 in particular raises blood levels of 25-hydroxyvitamin D more effectively than D2, which is why it dominates the supplement market.
Vitamin D5 does not share this absorption advantage. A study examining how human intestinal cells take up various vitamin D forms found that D4, D6, and D7 were all absorbed at rates comparable to D2 and D3, but D5 was the exception. Its uptake was notably lower.2PubMed Central. Uptake of Vitamins D2, D3, D4, D5, D6, and D7 Solubilized in Mixed Micelles by Human Intestinal Cells, Caco-2, an Enhancing Effect of Lysophosphatidylcholine on the Cellular Uptake, and Estimation of Vitamins D’ Biological Activities That finding is striking because it means D5 is not just “another vitamin D” that happens to have been passed over commercially. There is a biological reason it behaves differently: something about its particular side chain structure makes it harder for gut cells to pull it in through the same transport pathways used by the rest of the family.
The same study found that lysophosphatidylcholine, a fat molecule present in bile, enhanced the uptake of all vitamin D forms by roughly 2.5-fold. Even with that boost, D5 remained the outlier. For a supplement manufacturer looking at the vitamin D lineup, this poor absorption profile alone would be enough to cross D5 off the list. Why sell a form that your customers’ intestines struggle to absorb when D3 and D2 work well?
The Cancer Research That Put D5 on the Map
If D5 itself is a poor candidate for a supplement, a synthetic derivative of it has attracted serious scientific attention. The compound 1-alpha-hydroxyvitamin D5, usually written as 1α(OH)D5, is a lab-made analog that researchers began studying in the late 1990s as a potential cancer-prevention agent. The appeal was straightforward: the active form of vitamin D3 (calcitriol) had already shown anti-cancer properties in laboratory settings, but calcitriol at therapeutic doses raises blood calcium to dangerous levels. Researchers wanted a compound that could deliver the anti-cancer effects without the calcium toxicity.
1α(OH)D5 turned out to be a promising candidate. In organ culture experiments with mouse mammary glands, it inhibited the development of precancerous lesions after carcinogen exposure while producing far less of a calcium-raising effect than calcitriol.3JNCI: Journal of the National Cancer Institute. Prevention of Preneoplastic Mammary Lesion Development by a Novel Vitamin D Analogue, 1α-Hydroxyvitamin D5 The researchers described it as nontoxic across a wide range of concentrations yet potent against precancerous changes, a combination that calcitriol could not match.
Follow-up animal studies strengthened the case. When rats were exposed to a chemical carcinogen and then fed diets containing 1α(OH)D5, both the number of animals that developed mammary tumors and the number of tumors per animal dropped significantly, with no adverse effects on blood calcium levels.4Mutation Research – Fundamental and Molecular Mechanisms of Mutagenesis. Chemoprevention of mammary carcinogenesis by 1α-hydroxyvitamin D5, a synthetic analog of Vitamin D The compound appeared to work primarily during the promotion stage of cancer development rather than the initiation stage, suggesting it could interfere with how precancerous cells grow rather than preventing the initial DNA damage.
Breast and Colon Cancer Models
The research expanded beyond breast tissue. In a colon cancer model, 1α(OH)D5 proved highly effective at blocking the formation of aberrant crypt foci, which are clusters of abnormal cells in the colon lining considered early precursors to colorectal cancer. Mice given the compound showed reductions in these precancerous clusters of roughly 70 to 80 percent depending on whether the compound was administered during initiation, promotion, or throughout the entire experimental period.5The Journal of Steroid Biochemistry and Molecular Biology. Chemoprevention of chemically-induced mammary and colon carcinogenesis by 1α-hydroxyvitamin D5
Researchers investigating the mechanism found that 1α(OH)D5 influenced the beta-catenin signaling pathway, which plays a central role in how colon cells grow and differentiate. The compound reduced levels of beta-catenin and a downstream gene while increasing expression of the vitamin D receptor itself.5The Journal of Steroid Biochemistry and Molecular Biology. Chemoprevention of chemically-induced mammary and colon carcinogenesis by 1α-hydroxyvitamin D5 In plain terms, the compound seemed to turn down a growth-promoting signal in colon cells while turning up the receptor that allows vitamin D compounds to exert their protective effects.
The mammary tumor work showed a similar theme. In rats exposed to a different carcinogen, 1α(OH)D5 reduced tumor incidence during the promotional stage by about 37.5 percent. Across both breast and colon models, the pattern was consistent: the compound worked, it did not raise calcium dangerously, and its effects were most pronounced when precancerous cells were actively growing.
Prostate Cancer and a Different Mechanism
A separate line of research examined 1α(OH)D5 in prostate cancer cells, where an interesting twist emerged. The compound triggered cell death in castration-sensitive prostate cancer cells, but unlike calcitriol, it did not ramp up androgen receptor activity.6PubMed Central. Androgen Receptor regulation of Vitamin D receptor in response of castration-resistant prostate cancer cells to 1α-Hydroxyvitamin D5 – a calcitriol analog This distinction matters because androgen receptor signaling is what drives prostate cancer growth. A treatment that kills cancer cells while simultaneously stimulating the receptor that feeds the cancer is working against itself. Calcitriol has exactly that problem in prostate tissue. 1α(OH)D5 appeared to sidestep it.
The researchers also discovered that in androgen-independent prostate cancer cells (the kind that have stopped responding to hormone-deprivation therapy and are much harder to treat), the vitamin D receptor itself was downregulated. Removing androgens from the environment restored vitamin D receptor expression, which could in theory make those cells responsive to 1α(OH)D5 again. This line of work pointed to a possible role for the compound in combination with androgen-deprivation therapy, though the research has not progressed to human clinical trials.
Why None of This Led to a Supplement
The gap between “interesting lab results in cancer models” and “ingredient in a supplement bottle” is enormous, and vitamin D5 sits squarely in that gap. Several distinct barriers explain why.
First, the absorption issue already discussed means that plain vitamin D5 (sitocalciferol) is not an efficient way to raise vitamin D status in the body. If your goal is supporting bone health, immune function, or any of the other roles vitamin D plays in daily physiology, D3 does the job better and is cheap to produce. There is no nutritional case for choosing D5 over D3.
Second, the cancer research has been conducted almost entirely with 1α(OH)D5, which is a synthetic hydroxylated derivative, not something you would put in an over-the-counter vitamin pill. It behaves more like a drug candidate than a nutrient. The compound requires deliberate chemical synthesis and would need to go through pharmaceutical regulatory pathways, not supplement regulation, if it were ever to reach patients. Supplements in most countries are regulated as foods, not drugs, and a novel synthetic analog of a vitamin does not fit that category.
Third, and perhaps most fundamentally, the promising animal data has not been followed up with human clinical trials. The breast cancer prevention work dates to the late 1990s and early 2000s. The colon cancer and prostate cancer studies followed in the 2000s. Despite encouraging results in rodents, no large-scale human studies have tested whether 1α(OH)D5 prevents cancer in people. Without that evidence, no regulatory agency would approve it as a therapy, and no supplement company would market plain D5 when it lacks even the general health claims that support D2 and D3 sales.
The Broader Vitamin D Family and Why Only Two Forms Won
It is worth stepping back to consider why D2 and D3 came to dominate when there are at least six known forms. The answer is partly historical and partly biological. D3 is the form humans produce endogenously when sunlight hits the skin, so it had a natural head start in research and clinical use. D2 was identified in irradiated plant sterols early in the twentieth century and became the first commercially available supplement form, especially useful for vegetarian and vegan formulations. By the time researchers characterized D4 through D7, the supplement industry and clinical guidelines had already standardized around D2 and D3.
But the history alone does not explain the dominance. Biology reinforced it. D3 consistently outperforms D2 in raising and sustaining blood levels of the key circulating marker, 25-hydroxyvitamin D. The other forms have not demonstrated equivalent or superior performance. The intestinal uptake study that flagged D5 as a poor absorber also showed that D4, D6, and D7 were absorbed at rates similar to D2 and D3, which raises an interesting question: could any of those other forms theoretically work as supplements?2PubMed Central. Uptake of Vitamins D2, D3, D4, D5, D6, and D7 Solubilized in Mixed Micelles by Human Intestinal Cells, Caco-2, an Enhancing Effect of Lysophosphatidylcholine on the Cellular Uptake, and Estimation of Vitamins D’ Biological Activities In principle, perhaps. But no one has built the clinical evidence base to justify switching from the well-characterized forms. The regulatory and commercial inertia is massive. Every clinical guideline, every lab reference range, and every fortification standard worldwide is built around D2 and D3. Introducing a new form would require proving it is at least as good, and probably demonstrating some unique advantage that justifies the cost of retooling.
Common Misconceptions About Vitamin D5
A few misunderstandings circulate online about D5 that are worth clearing up. One is the idea that D5 is “natural” in the sense that you could get it from food in meaningful amounts. While beta-sitosterol, the precursor sterol, is common in plant foods, it does not convert to vitamin D5 in your body through normal metabolic pathways. The conversion requires UV irradiation under specific conditions. You are not making D5 from the sitosterol in your avocado.
Another misconception is that the cancer research on 1α(OH)D5 means you should seek out vitamin D5 supplements for cancer prevention. The compound used in those studies is not the same as plain sitocalciferol. It has been chemically modified with a hydroxyl group at a specific position, making it a different molecule with different biological activity. Even if someone managed to obtain plain D5, there is no evidence it would have the same anti-cancer properties as the hydroxylated research compound.
A third confusion involves conflating “not in supplements” with “suppressed” or “hidden by the industry.” The reality is more mundane. D5 does not appear in supplements because it is inferior to D3 for general health purposes, and its interesting derivative is a pharmaceutical research compound rather than a nutrient. There is no conspiracy, just a molecule that did not fit the supplement model.
Where the Research Stands Now
The 1α(OH)D5 research remains in preclinical territory. The animal studies from the early 2000s were genuinely promising: consistent reductions in tumor formation across multiple cancer types, a favorable safety profile with respect to calcium levels, and plausible molecular mechanisms involving well-known cancer signaling pathways. The prostate cancer work added a mechanistic wrinkle that distinguished the compound from calcitriol in a clinically meaningful way.
Yet the field has not advanced to human trials, and the reasons likely involve the economics of drug development as much as the science. Vitamin D analogs are not patentable in the same way that novel small molecules are, which limits the financial incentive for pharmaceutical companies to fund expensive clinical trials. Academic research groups, which produced most of the 1α(OH)D5 work, typically lack the resources to run large-scale cancer prevention trials. The result is a compound stuck in a familiar limbo: too promising to forget, too expensive to test properly, and too far from market to attract commercial investment.
For anyone curious about the broader vitamin D field, the D5 story is a useful reminder that “vitamin” does not always mean “supplement ingredient.” Some members of a vitamin family end up as everyday health products. Others end up as research tools, drug candidates, or biochemical curiosities. Vitamin D5 landed in the second category, and whether it ever moves out of it depends on funding and clinical ambition that have so far not materialized.